{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:15:29Z","timestamp":1761988529225,"version":"3.40.3"},"reference-count":185,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780444593894"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1016\/b978-0-444-59389-4.00001-x","type":"book-chapter","created":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T15:57:22Z","timestamp":1347638242000},"page":"1-39","source":"Crossref","is-referenced-by-count":3,"title":["Insights into the Role of Bioactivation Mechanisms in the Toxic Events Elicited by Non-nucleoside Reverse Transcriptase Inhibitors"],"prefix":"10.1016","author":[{"given":"Sofia A.","family":"Pereira","sequence":"first","affiliation":[]},{"given":"Riccardo","family":"Wanke","sequence":"additional","affiliation":[]},{"given":"M. Matilde","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Em\u00edlia C.","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Alexandra M.M.","family":"Antunes","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"The HIV outpatient study investigators declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0010","doi-asserted-by":"crossref","first-page":"a3172","DOI":"10.1136\/bmj.a3172","article-title":"HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity","volume":"338","author":"Deeks","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.fertnstert.2011.05.094","article-title":"Human immunodeficiency virus\/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals","volume":"96","author":"Kushnir","year":"2011","journal-title":"Fertil. Steril."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/03602530600959615","article-title":"Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction","volume":"38","author":"Uetrecht","year":"2006","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0025","series-title":"Adverse Drug Reactions","first-page":"165","article-title":"Role of reactive metabolites in drug-induced hepatotoxicity","volume":"196","author":"Srivastava","year":"2010"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0030","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2174\/092986709788803097","article-title":"Current concepts of mechanisms in drug-induced hepatotoxicity","volume":"16","author":"Russmann","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4065\/84.3.268","article-title":"Mechanisms of drug-induced allergy","volume":"84","author":"Schnyder","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cbi.2010.09.011","article-title":"Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity","volume":"192","author":"Park","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mrfmmm.2006.05.031","article-title":"Carcinogen-DNA adducts as a biomarker for cancer risk","volume":"600","author":"Rundle","year":"2006","journal-title":"Mutat. Res."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0050","first-page":"129","article-title":"Abnormalities in the metabolism of acetaminophen in patients infected with the human immunodeficiency virus (HIV)","volume":"19","author":"Esteban","year":"1997","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0753-3322(03)00043-X","article-title":"The importance of glutathione in human disease","volume":"57","author":"Townsend","year":"2003","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0060","unstructured":"World Health Organization, WHO guidelines on HIV\/AIDS. http:\/\/www.who.int\/rpc\/guidelines\/hiv_aids\/en\/index.html (accessed January 8, 2012)."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1473-3099(07)70262-1","article-title":"Is it safe to switch between efavirenz and nevirapine in the event of toxicity?","volume":"7","author":"Mehta","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0070","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","article-title":"Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection","volume":"27","author":"Powles","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1592\/phco.29.3.281","article-title":"Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents","volume":"29","author":"Fulco","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0080","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","volume":"47","author":"Das","year":"2004","journal-title":"J. Med. Chem."},{"year":"2009","author":"US Food and Drug Administration, Intelence (etravirine)","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0085"},{"year":"2011","series-title":"Tibotec Pharmaceuticals, EDURANT (rilpivirine) prescribing information","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0090"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(99)80009-9","article-title":"Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa","volume":"354","author":"Marseille","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa033500","article-title":"Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand","volume":"351","author":"Lallemant","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0105","unstructured":"Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection, August 16 (2010) 1\u2013219. http:\/\/aidsinfo.nih.gov\/ContentFiles\/PediatricGuidelines.pdf (accessed January 8, 2012)."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0110","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/00126334-200309011-00012","article-title":"Impact of nevirapine on lipid metabolism","volume":"34","author":"Clotet","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0115","unstructured":"Perinatal HIV Guidelines Working Group, Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, April 29 (2009) 1\u201390. http:\/\/aidsinfo.nih.gov\/ContentFiles\/PerinatalGL.pdf (accessed January 8, 2012)."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0120","first-page":"110","article-title":"Risk for immune-mediated liver reactions by nevirapine revisited","volume":"10","author":"Medrano","year":"2008","journal-title":"AIDS Rev."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0130","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","article-title":"Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection","volume":"20","author":"Pollard","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0135","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(98)24008-6","article-title":"Nevirapine-associated Stevens-Johnson syndrome","volume":"351","author":"Warren","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0140","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0145","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0150","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00126334-200404150-00014","article-title":"Hepatotoxicity associated with nevirapine use","volume":"35","author":"Baylor","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0155","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","article-title":"Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs","volume":"19","author":"Ananworanich","year":"2005","journal-title":"AIDS"},{"year":"2000","series-title":"Viramune (nevirapine), Dear healthcare professional letter","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0160"},{"year":"2000","series-title":"EMEA Public statement on Viramune (nevirapine), Severe and life-threatening cutaneous and hepatic reactions (EMEA\/11260\/00)","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0165"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0170","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/00002030-199815000-00026","article-title":"High incidence of nevirapine-associated rash in HIV-infected Chinese","volume":"12","author":"Ho","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/317536","article-title":"Sex differences in nevirapine rash","volume":"32","author":"Bersoff-Matcha","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0180","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/QAD.0b013e32832d3b54","article-title":"Nevirapine Toxicity Multicohort Collaboration, Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy","volume":"23","author":"Kesselring","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00126334-200402010-00003","article-title":"Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals","volume":"35","author":"Patel","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0190","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0195","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAD.0b013e3282f37812","article-title":"HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz","volume":"22","author":"Vitezica","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0205","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","article-title":"HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients","volume":"6","author":"Likanonsakul","year":"2009","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0215","doi-asserted-by":"crossref","unstructured":"O.A. Adaramoye, O.A. Adesanoye, O.M. Adewumi, O. Akanni, Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats, Hum. Exp. Toxicol. http:\/\/dx.doi.org\/10.1177\/0960327111424304 (Epub October 25, 2011), in press.","DOI":"10.1177\/0960327111424304"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0220","first-page":"873","article-title":"Physicians\u2019 Desk Reference, 63rd ed, Montvale","author":"VIRAMUNE (Nevirapine)","year":"2009","journal-title":"NJ"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0225","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1099-081X(199909)20:6<285::AID-BDD187>3.0.CO;2-V","article-title":"Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers","volume":"20","author":"Lamson","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0230","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003088-200039040-00004","article-title":"Nevirapine: pharmacokinetic considerations in children and pregnant women","volume":"39","author":"Mirochnick","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0235","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/507097","article-title":"Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration","volume":"43","author":"Haas","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0240","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/507101","article-title":"Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity","volume":"43","author":"Ritchie","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/FPC.0b013e32834dd82e","article-title":"Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV\/AIDS","volume":"22","author":"Liptrott","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0250","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0255","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0090-9556(24)14954-9","article-title":"Biotransformation of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0260","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0265","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/rcm.3136","article-title":"A liquid chromatography\/atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons","volume":"21","author":"Liu","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0270","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/bmc.1353","article-title":"A sensitive and specific liquid chromatography\/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons","volume":"24","author":"Ren","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135965350501000114","article-title":"Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0285","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0b013e3282ef9695","article-title":"CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children","volume":"21","author":"Saitoh","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0290","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1468-1293.2008.00689.x","article-title":"Cytochrome P450 2B6 516G ->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population","volume":"10","author":"Mahungu","year":"2009","journal-title":"HIV Med."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0295","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/FPC.0b013e32834a522e","article-title":"Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine","volume":"21","author":"Lehr","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0300","unstructured":"S.A. Pereira, M.M. Marques, U. Caixas, E.C. Monteiro, F.A. Beland, A.M.M. Antunes, Understanding the molecular basis for the hazards associated with nevirapine treatment, in: L.V. Berhardt (Ed.), Advances in Medicine and Biology, Vol. 44, Nova Science Publisher, Inc., Hauppauge, NY, in press."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0305","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejim.2004.04.007","article-title":"Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine","volume":"15","author":"Claes","year":"2004","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0310","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1365-2362.2000.00736.x","article-title":"N-acetylcysteine replenishes glutathione in HIV infection","volume":"30","author":"de Rosa","year":"2000","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0315","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1124\/dmd.108.021725","article-title":"Covalent binding and tissue distribution\/retention assessment of drugs associated with idiosyncratic drug toxicity","volume":"36","author":"Takakusa","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0320","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/tx800177k","article-title":"Demonstration of the metabolic pathway responsible for nevirapine induced skin rash","volume":"21","author":"Chen","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0325","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/tx034064+","article-title":"Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat","volume":"16","author":"Shenton","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0330","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/tx0501132","article-title":"Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat","volume":"18","author":"Shenton","year":"2005","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0335","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/tx0601152","article-title":"Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats","volume":"19","author":"Popovic","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0006-2952(93)90061-Z","article-title":"Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil","volume":"45","author":"Meisheri","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0345","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/ACI.0b013e32832dd13c","article-title":"Drug skin metabolites and allergic drug reactions","volume":"9","author":"Merk","year":"2009","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0350","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1124\/dmd.108.024851","article-title":"Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4","volume":"37","author":"Wen","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0355","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/mf.2006.28.7.1003580","article-title":"Rat CYP3A and CYP2B1\/2 were not associated with nevirapine-induced hepatotoxicity","volume":"28","author":"Walubo","year":"2006","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0360","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/dmd.109.028688","article-title":"Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries","volume":"38","author":"Srivastava","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0365","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1096\/fasebj.11.5.9141497","article-title":"Sulfation and sulfotransferases 4. Bioactivation of mutagens via sulfation","volume":"11","author":"Glatt","year":"1997","journal-title":"FASEB J."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0370","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/tx9902082","article-title":"Role of quinones in toxicology","volume":"13","author":"Bolton","year":"2000","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0375","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/1389200023337388","article-title":"The metabolism and toxicity of quinones, quinonimines and quinone-thioethers","volume":"3","author":"Monks","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0380","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1039\/c1ob06052j","article-title":"Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine","volume":"9","author":"Antunes","year":"2011","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0385","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/978-1-4684-5134-4_59","article-title":"Quinone imines as biological relevant intermediates","volume":"197","author":"Porubek","year":"1986","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0390","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1042\/bj2560757","article-title":"Abilities of peroxidases to catalyse peroxidase-oxidase oxidation of thiols","volume":"256","author":"Svensson","year":"1988","journal-title":"Biochem. J."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0395","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5005\/jcdp-9-1-84","article-title":"Oral adverse effects due to the use of nevirapine","volume":"9","author":"Moura","year":"2008","journal-title":"J. Contemp. Dent. Pract."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0400","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1601-0825.2001.70401.x","article-title":"Orofacial effects of antiretroviral therapies","volume":"7","author":"Scully","year":"2001","journal-title":"Oral Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0405","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1310\/hct0806-391","article-title":"Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites","volume":"8","author":"Hall","year":"2007","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0410","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/0889222041524670","article-title":"The relationship between nevirapine plasma concentrations and abnormal liver function tests","volume":"20","author":"Almond","year":"2004","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0415","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/aid.2005.21.555","article-title":"Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations","volume":"21","author":"de Requena","year":"2005","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0420","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1128\/AAC.00460-09","article-title":"Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis","volume":"53","author":"Cammett","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0425","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1086\/512086","article-title":"Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C","volume":"195","author":"Barreiro","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0430","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/00002030-200311070-00018","article-title":"Sex differences in nevirapine disposition in HIV-infected patients","volume":"17","author":"Regazzi","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0435","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1086\/429327","article-title":"Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects","volume":"40","author":"Rodr\u00edguez-Novoa","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0440","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0445","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.pharmtox.45.120403.100058","article-title":"The role of metabolic activation in drug-induced hepatotoxicity","volume":"45","author":"Park","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0450","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.toxlet.2003.12.015","article-title":"DNA and protein adducts as markers of genotoxicity","volume":"149","author":"Farmer","year":"2004","journal-title":"Toxicol. Lett."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0455","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1021\/tx900443z","article-title":"Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine\u2014a possible factor in nevirapine toxicity","volume":"23","author":"Antunes","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0460","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/tx8000972","article-title":"Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine","volume":"21","author":"Antunes","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0465","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00381551","article-title":"Urinary mercapturic acid excretion as a biological parameter of exposure to alkylating agents","volume":"39","author":"Seutter-Berlage","year":"1977","journal-title":"Int. Arch. Occup. Environ. Health"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0470","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJM197204062861404","article-title":"Albumin synthesis","volume":"286","author":"Rothschild","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0475","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/tx100186t","article-title":"Protein adducts as prospective biomarkers of nevirapine toxicity","volume":"23","author":"Antunes","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0480","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1570-0232(02)00172-1","article-title":"Protein adducts: quantitative and qualitative aspects of their formation, analysis and application","volume":"778","author":"T\u00f6rnqvist","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0485","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbi.2006.10.005","article-title":"N-terminal globin adducts as biomarkers for formation of butadiene derived epoxides","volume":"166","author":"Boysen","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0490","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chroma.2007.07.044","article-title":"Analysis of hemoglobin adducts of acrylamide and glycidamide by liquid chromatography-electrospray ionization tandem mass spectrometry, as exposure biomarkers in French population","volume":"1167","author":"Chevolleau","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0495","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijheh.2007.01.024","article-title":"Human biomonitoring: state of the art","volume":"210","author":"Angerer","year":"2007","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0500","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","article-title":"Efavirenz in the therapy of HIV infection","volume":"6","author":"Rakhmanina","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0505","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","article-title":"Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients","volume":"3","author":"P\u00e9rez-Molina","year":"2002","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0510","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","article-title":"A systematic review of the psychiatric side-effects of efavirenz","volume":"15","author":"Kenedi","year":"2011","journal-title":"AIDS Behav."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0515","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/QAD.0b013e32833c3281","article-title":"Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase","volume":"24","author":"Welz","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0520","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3109\/00207454.2010.520541","article-title":"Implications of efavirenz for neuropsychiatry: a review","volume":"120","author":"Cavalcante","year":"2010","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0525","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00042560-200203010-00004","article-title":"Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens","volume":"29","author":"Fumaz","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0530","first-page":"103","article-title":"Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review","volume":"11","author":"Mu\u00f1oz-Moreno","year":"2009","journal-title":"AIDS Rev."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0535","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14656566.8.6.851","article-title":"Efavirenz: a review","volume":"8","author":"Vrouenraets","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0540","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.0b013e31821670fb","article-title":"Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients","volume":"76","author":"Ciccarelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0545","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1468-1293.2003.00136.x","article-title":"Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz","volume":"4","author":"Lochet","year":"2003","journal-title":"HIV Med."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0550","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.qai.0000147523.41993.47","article-title":"Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence","volume":"38","author":"Fumaz","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0555","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/09540120410001716342","article-title":"Factors associated with efavirenz discontinuation in a large community-based sample of patients","volume":"16","author":"Spire","year":"2004","journal-title":"AIDS Care"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0560","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1128\/AAC.46.8.2687-2691.2002","article-title":"Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor","volume":"46","author":"Pilon","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0565","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hep.23647","article-title":"Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells","volume":"52","author":"Blas-Garc\u00eda","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0570","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1476-5381.2010.00866.x","article-title":"Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells","volume":"160","author":"Apostolova","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0575","doi-asserted-by":"crossref","first-page":"P161","DOI":"10.1186\/1758-2652-11-S1-P161","article-title":"Clinical concentrations of efavirenz (EFV) reduce cellular proliferation and viability in several human cell lines. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infections","volume":"11","author":"Apostolova","year":"2008","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0580","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s11064-011-0432-3","article-title":"Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions","volume":"36","author":"Streck","year":"2011","journal-title":"Neurochem. Res."},{"year":"2009","series-title":"Efavirenz: summary of product characteristics. European Medicines Evaluation Agency","author":"Bristol-Myers Squibb Pharmaceuticals Ltd","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0585"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0590","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/00003088-200140120-00002","article-title":"Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors","volume":"40","author":"Smith","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0595","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkq434","article-title":"Charter Group, Efavirenz concentrations in CSF exceed IC50 for wild-type HIV","volume":"66","author":"Best","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0600","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":"In vivo analysis of efavirenz metabolism in individuals with impaired CYP 2A6 function","volume":"19","author":"di Iulio","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0605","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/clpt.2008.271","article-title":"Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals","volume":"85","author":"Arab-Alameddine","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0610","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0615","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03368.x","article-title":"CYP2B6 (c.516G\u2013>T) and CYP2A6 (*9B and\/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients","volume":"67","author":"Kwara","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0620","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.fpc.0000230413.97596.fa","article-title":"Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study","volume":"16","author":"Motsinger","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0625","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP 2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0630","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/FTD.0b013e318160ce76","article-title":"Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy","volume":"30","author":"Pereira","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0635","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2165\/11592660-000000000-00000","article-title":"HIV\/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects","volume":"50","author":"Mukonzo","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0640","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication","volume":"13","author":"St\u00f6hr","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0645","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2125.2008.03238.x","article-title":"Efavirenz concentrations in HIV-infected patients with and without viral hepatitis","volume":"66","author":"Pereira","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0650","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0655","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Guti\u00e9rrez","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0660","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0665","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/135965350901400116","article-title":"Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study","volume":"14","author":"van Luin","year":"2009","journal-title":"Antivir. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0670","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/QAI.0b013e3181b061e6","article-title":"Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations","volume":"52","author":"van Luin","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0675","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1097\/QAD.0b013e32832e95f8","article-title":"Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial","volume":"23","author":"Read","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0680","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0090-9556(24)14935-5","article-title":"Identification and characterization of efavirenz metabolites by liquid chromatography\/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz","volume":"27","author":"Mutlib","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0685","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0690","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0695","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0700","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens","volume":"66","author":"Wyen","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0705","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0710","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0b013e318040b29e","article-title":"Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism","volume":"45","author":"Saitoh","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0715","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0720","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0725","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0730","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/00498254.2011.551849","article-title":"Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites","volume":"41","author":"Bae","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0735","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1128\/AAC.00883-10","article-title":"Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz","volume":"55","author":"Cho","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0740","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2217\/pgs.10.94","article-title":"Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients","volume":"11","author":"Elens","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0745","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.109.027706","article-title":"Glucuronidation of the antiretroviral drug efavirenz (EFV) by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine (AZT)","volume":"37","author":"Belanger","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0750","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/taap.2000.9055","article-title":"The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats","volume":"169","author":"Mutlib","year":"2000","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0755","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0760","doi-asserted-by":"crossref","first-page":"e27810","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients","volume":"6","author":"Yimer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0765","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/jpet.106.102525","article-title":"Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms","volume":"318","author":"Bumpus","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0770","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/toxsci\/kfl066","article-title":"Synaptic cysteine sulfhydryl groups as targets of electrophilic neurotoxicants","volume":"94","author":"LoPachin","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0775","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.taap.2011.09.008","article-title":"Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes","volume":"257","author":"Bumpus","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0780","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0300-483X(02)00195-6","article-title":"Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens","volume":"177","author":"Bolton","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0785","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/clpt.2010.172","article-title":"Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients","volume":"88","author":"Ngaimisi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0790","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5414\/CPP40507","article-title":"Population pharmacokinetic meta-analysis with efavirenz","volume":"40","author":"Barrett","year":"2002","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0795","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":"Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP 2B6 and CYP 3A4 inducers","volume":"320","author":"Faucette","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","article-title":"Hepatic but not intestinal CYP 3A4 displays dose-dependent induction by efavirenz in humans","volume":"72","author":"Mouly","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0805","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0028-3908(03)00136-9","article-title":"Smoking, alcoholism and genetic polymorphisms alter CYP 2B6 levels in human brain","volume":"45","author":"Miksys","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0810","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/npp.2010.202","article-title":"Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects","volume":"36","author":"Khokhar","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0815","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"year":"2010","series-title":"Tibotec Therapeutics, Intelence\u00ae (etravirine) tablets prescribing information","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0820"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0825","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/591705","article-title":"Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection","volume":"47","author":"Montaner","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0830","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2010.181","article-title":"Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients","volume":"88","author":"Kakuda","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0835","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/10895940-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of etravirine","volume":"48","author":"Sch\u00f6ler-Gy\u00fcre","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0840","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/14787210.6.4.427","article-title":"Etravirine for the treatment of HIV infections","volume":"4","author":"Seminari","year":"2008","journal-title":"Expert Rev. Anti Infect. Ther."},{"article-title":"Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5+1 cocktail","year":"2008","author":"Sch\u00f6ler-Gy\u00fcre","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0845"},{"article-title":"the Swiss HIV Cohort Study, Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals","year":"2011","author":"Lubomirov","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0850"},{"article-title":"Time-dependent cytochrome P450-mediated metabolism of etravirine in primary human hepatocytes, P260","year":"2011","author":"Yanakakis","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0855"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0860","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1128\/AAC.01527-10","article-title":"Interaction potential of etravirine with drug transporters assessed in vitro","volume":"55","author":"Zembruski","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0865","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200948040-00001","article-title":"Drug interactions with new and investigational antiretrovirals","volume":"48","author":"Brown","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0870","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3851\/IMP1652","article-title":"Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine","volume":"15","author":"Kakuda","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0875","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0091270007310387","article-title":"Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers","volume":"48","author":"Sch\u00f6ller-Gy\u00fcre","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0880","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cbdv.200890199","article-title":"The biochemistry of drug metabolism\u2014an introduction: part 4. Reactions of conjugation and their enzymes","volume":"5","author":"Testa","year":"2008","journal-title":"Chem. Biodivers."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0885","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/tx800051y","article-title":"Quantitative high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry analysis of the adenine-guanine cross-links of 1,2,3,4-diepoxybutane in tissues of butadiene-exposed B6C3F1 mice","volume":"21","author":"Goggin","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0890","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1021\/tx9003215","article-title":"Identification of furan metabolites derived from cysteine-cis-2-butene-1,4-dial-lysine, cross-links","volume":"23","author":"Lu","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0895","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"year":"2011","series-title":"Gilead Sciences, COMPLERA\u00ae (emtricitabine\/rilpivirine\/tenofovir disoproxil fumarate) tablets, Foster City","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0900"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0905","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0910","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1517\/13543780903055056","article-title":"Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor","volume":"18","author":"Garvey","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"article-title":"Hoetelmans, The effect of TMC278, a next generation NNRTI, on CYP3A activity in vivo","year":"2009","author":"Crauwels","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0915"},{"article-title":"Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers, EACS","year":"2009","author":"Lachau-Durand","key":"10.1016\/B978-0-444-59389-4.00001-X_bb0920"},{"key":"10.1016\/B978-0-444-59389-4.00001-X_bb0925","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/10408440591002183","article-title":"Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health","volume":"35","author":"O'Brien","year":"2005","journal-title":"Crit. Rev. Toxicol."}],"container-title":["Advances in Molecular Toxicology","Advances in Molecular Toxicology Volume 6"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T14:29:20Z","timestamp":1744122560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B978044459389400001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9780444593894"],"references-count":185,"URL":"https:\/\/doi.org\/10.1016\/b978-0-444-59389-4.00001-x","relation":{},"ISSN":["1872-0854"],"issn-type":[{"type":"print","value":"1872-0854"}],"subject":[],"published":{"date-parts":[[2012]]}}}